Effects of a soluble guanylate cyclase stimulator, BAY 41-8543, upon right ventricular function in experimental pulmonary embolism Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008
Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014
Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Source: Eur Respir J 2009; 33: 785-792 Year: 2009
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013
Blunted effects of rho-kinase inhibitor, fasudil, on pulmonary arterial pressure in Yak, a high altitude-adapted animal Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Source: Eur Respir Rev 2009; 19: 68-71 Year: 2010
Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
Activation of AMPK inhibits pulmonary arterial remodeling Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial Source: Eur Respir J 2013; 41: 853-860 Year: 2013
Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501 Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
Modulation of symmetric dimethyarginine formation by apelin in human pulmonary endothelial cells Source: International Congress 2015 – Translational research in respiratory care: new findings Year: 2015
Role of the TrkA receptor in experimental severe pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015
Repeated embolization and fibrinolysis inhibition induce chronic thromboembolic pulmonary hypertension in rabbits Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013
Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014